IncellDx raises $3 million to detect diseases

Molecular diagnostics company IncellDx has raised $3 million in a first round of funding, according to a filing with the SEC. Based in Menlo Park, Calif., the company’s products detect and monitor diseases including breast cancer, ovarian cancer, HIV/AIDS, HPV/cervical cancer, and hepatitis. In May, IncellDx announced that it will work with Accuri Cytometers on a cervical cancer screening tool.